Nuvation Bio's IBTROZI Shows Durable Responses in Long-Term Lung Cancer Trials — Nuvation Bio Inc.

Event summary

Nuvation Bio presented long-term follow-up data from TRUST-I and TRUST-II trials for IBTROZI (taletrectinib) at AACR 2026, showing a median duration of response of 49.7 months and a median progression-free survival of 46.1 months in TKI-naïve patients.
IBTROZI demonstrated a high overall response rate of 89.8% in TKI-naïve patients and robust CNS activity with an intracranial response rate of 76.5% in TKI-naïve patients and 65.6% in TKI-pretreated patients with brain metastases.
The safety profile of IBTROZI was manageable, with low rates of neurologic side effects and no new safety signals identified.
Preclinical data presented at AACR showed taletrectinib's potential for suppressing TRKB-mediated lung cancer cell migration.

The big picture

Nuvation Bio's IBTROZI is positioning itself as a next-generation ROS1 inhibitor with durable responses and a favorable safety profile, addressing a significant unmet need in the treatment of advanced ROS1-positive non-small cell lung cancer. The long-term data presented at AACR 2026 reinforces its potential to redefine the standard of care, particularly in patients with brain metastases. The company's strategic focus on tackling tough challenges in cancer treatment aligns with broader industry trends towards more targeted and effective therapies.

What we're watching

Regulatory Approvals: The pace at which IBTROZI gains regulatory approvals in additional markets, following its acceptance for full approval consideration by the European Medicines Agency in March 2026.
Clinical Trial Progress: The progress and results of the ongoing TRUST-IV and TRUST-III Phase 3 studies, which will further validate IBTROZI's efficacy and safety profile.
Competitive Dynamics: How IBTROZI's durable responses and manageable safety profile will position it against existing ROS1 inhibitors like entrectinib and crizotinib in the market.